This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 20, 2013 /PRNewswire/ -- Harwood Feffer LLP (
www.hfesq.com) is investigating potential claims against the board of directors of Transcept Pharmaceuticals, Inc. ("Transcept" or the "Company") (NASDAQ: TSPT) concerning the proposed acquisition of the Company by Retrophin, Inc. ("Retrophin").